Back to today’s briefing

Story perspectives

FDA-Approved Drug Cuts Tau Protein by 70%!

8/13/2025

34 3

Summary

Story summary

A groundbreaking discovery from the University of Pittsburgh reveals that pyrvinium pamoate, an FDA-approved drug, can significantly reshape nuclear speckles, leading to a remarkable 70% reduction in tau protein buildup in tauopathy models. This innovative strategy holds great promise for combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with clinical trials on the horizon to assess its potential in humans.

1 of 1

Story summary

A groundbreaking discovery from the University of Pittsburgh reveals that pyrvinium pamoate, an FDA-approved drug, can significantly reshape nuclear speckles, leading to a remarkable 70% reduction in tau protein buildup in tauopathy models. This innovative strategy holds great promise for combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with clinical trials on the horizon to assess its potential in humans.